



DIVISION OF  
**PHARMACOEPIDEMIOLOGY &  
PHARMACOECONOMICS**

DEPARTMENT OF MEDICINE  
BRIGHAM AND WOMEN'S HOSPITAL  
HARVARD MEDICAL SCHOOL



## Michael Fischer, MD, MS

Brigham & Women's Hospital  
Department of Medicine  
Division of Pharmacoepidemiology & Pharmacoeconomics

[Also Associate Professor of Medicine,  
Harvard Medical School]

1620 Tremont Street, Suite 3030,  
Boston, MA 02120  
[mfischer@partners.org](mailto:mfischer@partners.org)  
Phone: 617-278-0930 | Fax: 617-232-8602



Michael Fischer, MD, MS, is an Associate Professor of Medicine at Harvard Medical School and an Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics at [Brigham and Women's Hospital](#). His research interests include prescription drug reimbursement policy, electronic prescribing, and medication adherence. Dr. Fischer directs the [National Resource Center for Academic Detailing](#), an initiative funded by the Agency for Healthcare Research and Quality to promote increased use of educational outreach to healthcare providers. Additional research interests include appropriate use of prescription drugs and assessment of complications of prescription drug therapy. Dr. Fischer attended [Harvard College](#), [Yale University School of Medicine](#), and [Harvard School of Public Health](#), and completed residency training in Primary Care Internal Medicine at Brigham and Women's Hospital. His clinical practice is in primary care at [The Phyllis Jen Center for Primary Care](#).

### Selected Publications | [Current PubMed Search Results](#)

- **Fischer MA**, Avorn J. [Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans](#). *Health Serv Res* 2003;38:1051-63.
- **Fischer MA**, Avorn J. [Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA](#) 2004;291:1850-6.
- **Fischer MA**, Avorn J. [Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit](#). *Pharmacoepidemiol Drug Safety* 2004;13:207-14.
- **Fischer MA**, Lilly CM, Churchill WW, Baden LR, Avorn J. [An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre](#). *Drug Saf* 2004;27:1253-61.
- **Fischer MA**, Schneeweiss S, Avorn J, Solomon DH. [Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors](#). *N Engl J Med* 2004;351:2187-94.
- **Fischer MA**, Solomon DS, Teich JM, Avorn J. [Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients](#). *Arch Intern Med* 2003;163(24):2585-9.

- **Fischer MA**, Winkelmaye WC, Rubin RH, Avorn J. [The hepatotoxicity of antifungal medications in bone marrow transplant recipients](#). *Clin Infect Dis* 2005;41:301-7.
- **Fischer MA**, Servi AD, Polinski JM, Wang PS. [Restrictions for antidepressant medications in children – a review of Medicaid policy](#). *Psychiatric Services* 2007; 58(1):135-8.
- **Fischer MA**, Morris CA, Winkelmaye WC, Avorn J. [Non-oncologic use of human recombinant erythropoietin in hospitalized patients](#). *Archives of Internal Medicine* 2007;167:840-6.
- Polinski JM, Wang PS, **Fischer MA**. [Medicaid’s prior authorization program and access to atypical antipsychotic medications](#). *Health Affairs* 2007; 26:750-60.
- **Fischer MA**, Choudhry NK, Winkelmaye WC. [Impact of Medicaid prior authorization on angiotensin receptor blockers: Can policy promote rational prescribing?](#) *Health Affairs* 2007; 26: 800-7.
- Patrick AM, Avorn J, Winkelmaye WC, **Fischer MA**. [Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis](#). *Pharmacoeconomics* 2007;25: 949-61.
- **Fischer MA**, Stedman MR, Vogeli C, Ferris TG, Weissman JS. [Uptake of electronic prescribing in community-based practices](#). *Journal of General Internal Medicine* 2008; 23: 358-63.
- **Fischer MA**, Stedman MS, Vogeli C, Ferris T, Brookhart MA, Weissman JS. [Effect of electronic prescribing with formulary decision support on medication use and costs](#). *Archives of Internal Medicine* 2008; 168:2433-9.
- **Fischer MA**, Polinski JM, Servi AD, Agnew-Blais J, Kaci L, Solomon, DH. [Prior authorization for biologic DMARDs: A description of United States Medicaid programs](#). *Arthritis Care & Research* 2008; 59:1611-17.
- **Fischer MA**, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, Weissman JS. [Primary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions](#). *Journal of General Internal Medicine* 2010; 25(4):284–90.
- Agarwal R, Angst CM, Desroches C, **Fischer MA**. [Technological viewpoints \(frames\) about electronic prescribing in physician practices](#). *Journal of the American Medical Informatics Association* 2010; 17(4): 425-431.
- Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, Kesselheim AS, Brookhart MA, **Fischer MA**. [State generic substitution laws can lower drug outlays under Medicaid](#). *Health Affairs* 2010; 29(7):1383-90.
- Avorn J, **Fischer MA**. [“Bench to behavior”](#): translating comparative effectiveness research into improved clinical practice. *Health Affairs* 2010; 29(10):1891-1900.
- Desroches C, Angst CM, Agarwal R, **Fischer MA**. [Differences Between Integrated And Stand-Alone E-Prescribing Systems Have Implications For Future Use](#). *Health Affairs* 2010; 29(12):2268-77.
- Solomon DH, Mogun H, Garneau K, **Fischer MA**. [The risk of fractures in older adults using anti-hypertensive medications](#). *Journal of Bone and Mineral Research* 2011; 26(7):1561-7.
- **Fischer MA**, Choudhry NK, Brill G, Avorn J, Schneeweiss S, Liberman J, Hutchins D, Brennan TA, Shrank WH. [Trouble getting started: predictors of primary medication non-adherence](#). *American Journal of Medicine* 2011; 124(11):1081.e9.
- **Fischer MA**, Avorn J. [Academic Detailing Can Play A Key Role In Assessing and Implementing Comparative Effectiveness Research Findings](#). *Health Affairs* 2012; 31(10):2206-12.

- Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K, Mogun H, Ecker JL, **Fischer MA**. [Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population](#). Hypertension. 2012; 60(4):913-20.